Skip to content
10-K

Annual Report

Coya Therapeutics, Inc. COYA

0001193125-26-107281

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 12, 2026 23.46M sh
Shares Diluted FY 2025 · Dec 31, 2025 16.73M sh
Shares Diluted FY 2025 · Dec 31, 2024 15.24M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$10.74M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$10.29M
Cash And Equivalents FY 2025 · Dec 31, 2025 $46.82M
Cash And Equivalents FY 2025 · Dec 31, 2024 $38.34M
Stockholders Equity FY 2025 · Dec 31, 2025 $43.03M
Stockholders Equity FY 2025 · Dec 31, 2024 $39.58M
Stockholders Equity FY 2025 · Dec 31, 2023 $35.64M
Current Liabilities FY 2025 · Dec 31, 2025 $5.87M
Current Liabilities FY 2025 · Dec 31, 2024 $3.82M
Total Liabilities FY 2025 · Dec 31, 2025 $6.92M
Total Liabilities FY 2025 · Dec 31, 2024 $4.77M
Current Assets FY 2025 · Dec 31, 2025 $49.94M
Current Assets FY 2025 · Dec 31, 2024 $44.31M
Total Assets FY 2025 · Dec 31, 2025 $49.95M
Total Assets FY 2025 · Dec 31, 2024 $44.35M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.27
Eps Diluted FY 2025 · Dec 31, 2024 −$0.98
Eps Basic FY 2025 · Dec 31, 2025 −$1.27
Eps Basic FY 2025 · Dec 31, 2024 −$0.98
Sga Expense FY 2025 · Dec 31, 2025 $11.45M
Sga Expense FY 2025 · Dec 31, 2024 $8.89M
Net Income FY 2025 · Dec 31, 2025 −$21.23M
Net Income FY 2025 · Dec 31, 2024 −$14.88M
Operating Income FY 2025 · Dec 31, 2025 −$22.56M
Operating Income FY 2025 · Dec 31, 2024 −$17.25M
Revenue FY 2025 · Dec 31, 2025 $7.95M
Revenue FY 2025 · Dec 31, 2024 $3.55M